The 12-month prevalent cases of major depressive disorder (MDD) is expected to increase from 53.37 million cases in 2019 to 55.36 million cases in 2029, at an annual growth rate (AGR) of 0.37% across the eight major markets *8MM. Out of the 8MM, Spain is expected to grow at an annual growth rate (AGR) of 1.23% (2019–2029), followed by Italy (0.73%) and the US (0.53%).
GlobalData’s latest report notes that the major drivers for the upward trend of 12-month total prevalent cases of MDD in the 8MM over the next decade may be driven by changes in the population demographics of these markets, rather than an increase or decrease in the 12-month total prevalence of MDD.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “MDD is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems. Little is known about the etiology of MDD; however, research suggests that there may be combinations of genetic, biological, environmental and psychological factors that potentially increase the risk of MDD.”
In Spain and Italy, the elderly population are at a higher risk for MDD compared to that in the rest of the 8MM. Therefore, the aging population in Spain and Italy contribute to the increase in the 12-month prevalent cases of MDD in these markets.
The guidelines for MDD diagnosis have changed over time and are becoming broader and more inclusive, so some persons who would not have been diagnosed under the previous guidelines would now be diagnosed with MDD. This epidemiology analysis used the DSM-5 as the diagnostic criteria for 12-month total prevalence of MDD.
*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and Canada.
Major depressive disorder (MDD) Epidemiology Report and Model provide an overview of the risk factors and the global and historical trends for MDD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
The report includes a 10-year epidemiological forecast for the 12-month total prevalent cases of MDD based on the American Psychiatric Association’s (APA) Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. The 12-month total prevalent cases of MDD (including diagnosed and undiagnosed) are further segmented by age, sex, and severity (mild, moderate, and severe).
This epidemiology forecast for MDD is supported by historical data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast total prevalent cases of MDD across these markets.
The MDD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The MDD Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Quantify patient populations in the global MDD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for MDD therapeutics in each of the markets covered.
- Understand magnitude of MDD by severity.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Major Depressive Disorder: Executive Summary
2.2 Related Reports
2.3 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.2 Forecast Assumptions and Methods
3.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD
3.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD by Severity
3.5 Epidemiological Forecast for MDD (2019–2029)
3.5.1 12-Month Total Prevalent Cases of MDD
3.5.2 Age-Specific 12-Month Total Prevalence of MDD
3.5.3 Sex-Specific 12-Month Prevalent Cases of MDD
3.5.4 12-Month Total Prevalent Cases of MDD by Severity for Ages <18 Years
3.6.1 Epidemiological Forecast Insight
3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
List of Tables
Table 1: Summary of Newly Added Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for MDD
List of Figures
Figure 1: 8MM, 12-Month Total Prevalent Cases of MDD, Both Sexes, N, Ages ≥18 Years, 2019 and 2029
Figure 2: 8MM, 12-Month Total Prevalence of MDD (%), Men and Women, Ages ≥18 Years, 2019
Figure 3: 8MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of MDD
Figure 4: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD, by Severity
Figure 5: 8MM, 12-Month Total Prevalent Cases of MDD, N, Both Sexes, Ages ≥18 Years, 2019
Figure 6: 8MM, 12-Month Total Prevalent Cases of MDD by Age, N, Both Sexes, 2019
Figure 7: 8MM, 12-Month Total Prevalent Cases of MDD by Sex, N, Ages ≥18 Years, 2019
Figure 8: 8MM, Total Prevalent Cases of MDD by Severity, N, Ages ≥18 Years, 2019